Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. RNA
stocks logo

RNA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.98M
-33.35%
-1.281
+60.14%
2.38M
+51.18%
-1.285
+42.78%
2.38M
-38.18%
-1.319
+8.99%
Estimates Revision
The market is revising Upward the revenue expectations for Avidity Biosciences, Inc. (RNA) for FY2025, with the revenue forecasts being adjusted by 132.79% over the past three months. During the same period, the stock price has changed by 42.06%.
Revenue Estimates for FY2025
Revise Upward
up Image
+132.79%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+3.17%
In Past 3 Month
Stock Price
Go Up
up Image
+42.06%
In Past 3 Month
Wall Street analysts forecast RNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RNA is 71.71 USD with a low forecast of 53.00 USD and a high forecast of 96.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
Wall Street analysts forecast RNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RNA is 71.71 USD with a low forecast of 53.00 USD and a high forecast of 96.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
10 Hold
0 Sell
Moderate Buy
Current: 71.540
sliders
Low
53.00
Averages
71.71
High
96.00
Current: 71.540
sliders
Low
53.00
Averages
71.71
High
96.00
TD Cowen
Ritu Baral
Buy -> Hold
downgrade
$78 -> $74
2025-10-28
Reason
TD Cowen
Ritu Baral
Price Target
$78 -> $74
2025-10-28
downgrade
Buy -> Hold
Reason
TD Cowen analyst Ritu Baral downgraded Avidity Biosciences (RNA) to Hold from Buy with a price target of $74, down from $78, after the company entered into a merger agreement with Novartis (NVS) for $72 per share.
Chardan
Keay Nakae
Buy -> Neutral
downgrade
$72
2025-10-28
Reason
Chardan
Keay Nakae
Price Target
$72
2025-10-28
downgrade
Buy -> Neutral
Reason
Chardan analyst Keay Nakae downgraded Avidity Biosciences (RNA) to Neutral from Buy with a $72 price target after Novartis (NVS) announced an agreement to acquire Avidity for $72 per share in cash. The acquisition is expected to close in the first half of 2026, the analyst tells investors in a research note.
Citi
Geoff Meacham
Buy -> Neutral
downgrade
$72
2025-10-28
Reason
Citi
Geoff Meacham
Price Target
$72
2025-10-28
downgrade
Buy -> Neutral
Reason
Citi analyst Geoff Meacham downgraded Avidity Biosciences (RNA) to Neutral from Buy with an unchanged price target of $72 after the company entered into a merger agreement with Novartis (NVS) for $72 per share. Citi believes a competitive bid is unlikely.
BofA
BofA
downgrade
$72
2025-10-27
Reason
BofA
BofA
Price Target
$72
2025-10-27
downgrade
Reason
BofA moved to No Rating on Avidity Biosciences (RNA) after the company announced that it has entered into an agreement to be acquired by Novartis (NVS) for about $12B, or $72 per share. Given the deal, the stock is no longer trading on fundamentals, the analyst tells investors.
Citi
Geoff Meacham
Buy -> Neutral
downgrade
$72
2025-10-27
Reason
Citi
Geoff Meacham
Price Target
$72
2025-10-27
downgrade
Buy -> Neutral
Reason
Citi analyst Geoff Meacham downgraded Avidity Biosciences (RNA) to Neutral from Buy with an unchanged price target of $72 after the announcement of the proposed acquisition by Novartis (NVS).
Leerink
Leerink
Outperform -> Market Perform
downgrade
$72
2025-10-27
Reason
Leerink
Leerink
Price Target
$72
2025-10-27
downgrade
Outperform -> Market Perform
Reason
Leerink downgraded Avidity Biosciences (RNA) to Market Perform from Outperform with a $72 price target after Novartis (NVS) announced an agreement to acquire Avidity for $72 per share in cash.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Avidity Biosciences Inc (RNA.O) is -13.62, compared to its 5-year average forward P/E of -7.41. For a more detailed relative valuation and DCF analysis to assess Avidity Biosciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-7.41
Current PE
-13.62
Overvalued PE
-3.65
Undervalued PE
-11.16

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.48
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-1.23
Undervalued EV/EBITDA
-7.72

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
230.36
Current PS
0.00
Overvalued PS
450.05
Undervalued PS
10.67
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

RNA News & Events

Events Timeline

(ET)
2025-11-10
16:11:43
Avidity Biosciences Announces Q3 Earnings Per Share of $1.27, Exceeding Consensus Estimate of $1.10
select
2025-10-27 (ET)
2025-10-27
12:00:06
Avidity Biosciences Sees 42.5% Increase
select
2025-10-27
10:00:03
Avidity Biosciences Sees 42.8% Increase
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.5
12-03NASDAQ.COM
Significant ETF Inflows: XBI, EXAS, RVMD, RNA

  • 52-Week Range of XBI: XBI's share price has a 52-week low of $66.66 and a high of $123.47, with the last trade recorded at $120.40.

  • 200-Day Moving Average: The article suggests that comparing the current share price to the 200-day moving average can be a useful technical analysis tool.

  • ETFs Trading Mechanism: Exchange-traded funds (ETFs) function like stocks, where investors buy and sell "units" that can be created or destroyed based on demand.

  • Impact of Inflows and Outflows: Monitoring week-over-week changes in shares outstanding helps identify ETFs with significant inflows or outflows, which can affect the underlying holdings.

[object Object]
Preview
7.0
12-02PRnewswire
Avidity Biosciences Acquired by Novartis for $72 per Share
  • Acquisition Investigation: Halper Sadeh LLC is investigating Avidity Biosciences, Inc. (NASDAQ:RNA) for its sale to Novartis at $72 per share in cash, potentially violating federal securities laws and fiduciary duties to shareholders.
  • Shareholder Rights: The law firm encourages Avidity shareholders to contact them immediately to learn about their rights and options, indicating that shareholder interests may be at risk in the transaction.
  • Merger Scrutiny: Halper Sadeh LLC is also examining the merger between Third Coast Bancshares, Inc. (NYSE:TCBX) and Keystone Bancshares, Inc., which may involve fiduciary duty issues affecting shareholders.
  • Legal Support: The firm offers legal assistance on a contingency fee basis, ensuring that affected investors can seek increased compensation and disclosures without upfront costs, highlighting their commitment to protecting shareholder rights.
[object Object]
Preview
9.0
11-26NASDAQ.COM
Sarepta's Shares Climb Following Encouraging News on DM1 Treatment

  • Sarepta Therapeutics' Stock Surge: Shares of Sarepta Therapeutics rose 7% following positive updates on its phase I/II study of SRP-1003, a potential treatment for type 1 myotonic dystrophy, including successful patient enrollment and safety committee approval.

  • Milestone Payments and Partnerships: The announcement triggered a $200 million milestone payment to Arrowhead Pharmaceuticals, part of a multi-billion-dollar licensing deal, with Sarepta having previously made a $100 million payment earlier this year.

  • Investor Sentiment: Despite the stock's significant decline of nearly 85% year-to-date, investor optimism has increased due to the positive study updates, contrasting with challenges faced by other companies in the same therapeutic area.

  • Future Developments: Sarepta is currently dosing patients in the fourth cohort of the study and plans to begin the fifth cohort in early 2026, with initial data expected early next year for SRP-1003 and other clinical-stage programs.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Avidity Biosciences Inc (RNA) stock price today?

The current price of RNA is 71.54 USD — it has decreased -0.06 % in the last trading day.

arrow icon

What is Avidity Biosciences Inc (RNA)'s business?

Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. The Del-desiran is designed to treat people with myotonic dystrophy type 1 (DM1) and is in the global Phase III HARBOR trial and in the ongoing MARINA-OLE trial in people with DM1. The Delpacibart braxlosiran is the first investigational therapy designed to directly target DUX4 in people living with facioscapulohumeral muscular dystrophy (FSHD). The Del-zota is designed for people with Duchenne muscular dystrophy (DMD) and is in development with the Phase II EXPLORE44 open-label extension (OLE) study.

arrow icon

What is the price predicton of RNA Stock?

Wall Street analysts forecast RNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RNA is 71.71 USD with a low forecast of 53.00 USD and a high forecast of 96.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Avidity Biosciences Inc (RNA)'s revenue for the last quarter?

Avidity Biosciences Inc revenue for the last quarter amounts to 12.48M USD, increased 434.03 % YoY.

arrow icon

What is Avidity Biosciences Inc (RNA)'s earnings per share (EPS) for the last quarter?

Avidity Biosciences Inc. EPS for the last quarter amounts to -1.27 USD, increased 95.38 % YoY.

arrow icon

What changes have occurred in the market's expectations for Avidity Biosciences Inc (RNA)'s fundamentals?

The market is revising Upward the revenue expectations for Avidity Biosciences, Inc. (RNA) for FY2025, with the revenue forecasts being adjusted by 132.79% over the past three months. During the same period, the stock price has changed by 42.06%.
arrow icon

How many employees does Avidity Biosciences Inc (RNA). have?

Avidity Biosciences Inc (RNA) has 391 emplpoyees as of December 05 2025.

arrow icon

What is Avidity Biosciences Inc (RNA) market cap?

Today RNA has the market capitalization of 10.78B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free